Abstract:Objective: To identify the factors associated with long-term survival and guide the decision for primary surgery in patients with advanced high-grade serous ovarian cancer(HGSOC). Methods: In this case-control study, clinical parameters, including surgical and non-surgical associated factors, were collected and compared between the patients with short-term (<2 years) and long-term (>5 years) survival who all underwent primary debulking surgery (PDS) followed by carboplatin and paclitaxel chemotherapy from January 2004 to December 2016. Univariate analysis was examined by chi-square test and multivariate analysis was performed by logistic regression analysis. Results: There were 95 cases long-term survival (LTS group) and 77 cases short-term survival (STS group) in 698 newly diagnosed HGSOC patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅲc and Ⅳ who met include and exclude criteria. (1) Univariate analysis showed that the proportion of complete cytoreduction with no visible residual disease (R0) at PDS and platinum sensitivity in LTS group were significantly higher than those in STS group (P<0.01). The surgical complexity score (SCS), the preoperative serum CA125 level and the ascites volume in the LTS group were significantly lower than those of the STS group (all P<0.05). In the LTS group, the preoperative incidence of lesions in retrograde peritoneum of the bladder, serosal and mesangial membrane of the small intestine, upper abdominal peritoneum and liver parenchyma were significantly lower than those in the STS group (all P<0.05). Multivariate logistic regression analysis showed that platinum sensitivity (OR=0.016, 95%CI: 0.004-0.063, P<0.01), ascites volume >500 ml (OR=3.193, 95%CI: 1.285-7.930, P=0.012), and SCS ≥8 (OR=17.433, 95%CI: 2.281-133.25, P=0.003) were independent factors affecting long-term survival (P>0.05). (2) Totally 37 of 95 in long-term survival and 16 of 77 in short-term survival achieved R0 cytoreduction at PDS. Univariate analysis showed that preoperative serum CA125 level, preoperative lesion score, preoperative lesion (DS) score, ascites volume, platinum sensitivity,and SCS were significantly correlated with the R0 PDS (all P<0.05). Multivariate analysis showed that ascites volume >500 ml (OR=5.199, 95%CI: 2.015-13.409, P=0.001), DS >2 (OR=15.264, 95%CI: 5.843-39.874, P<0.01) and SCS ≥4 (OR=4.176, 95%CI: 1.618-10.777, P=0.003) were independent factors associated with R0 cytoreduction. In patients with DS ≤2 or SCS <4, but not those with DS >2 or SCS ≥4, R0 cytoreduction was significantly associated with long-term survival. Conclusion: The intrinsic biology of tumor is the factor influencing long-term survival of advanced HGSOC patients, and those who present with wide intraperitoneal metastases and need to remove multiple organs may not benefit from R0 cytoreduction.

Platinum-resistance in advanced epithelial ovarian carcinomas and treatment for different recurrent diseases

Platinum-resistant in 244 epithelial ovarian carcinomas and the effect of chemosensitivity on prognosis

Clinical features of recurrent ovarian carcinoma and prognosis comparison of different treatment

Predictive Factors for Initial Treatment of Advanced Epithelial Ovarian Cancer

Prediction of Chemoresistance in Epithelial Ovarian Cancer by Clinical Factors

Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy

[Related-Factor Analysis on Efficacy of Re-Platinum Chemotherapy in Platinum-Sensitive Recurrent Ovarian Carcinoma].

Multidisciplinary Treatment of Recurrent Epithelial Ovarian Carcinoma and Prognostic Analysis

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

The Different Prognostic Significance of Platinum-Based Intraperitoneal Chemotherapy in Advanced Epithelial Ovarian Cancer

Clinical Outcomes and Prognostic Factors of Patients with Epithelial Ovarian Cancer Subjected to First-Line Treatment: a Retrospective Study of 251 Cases

XRCC1 Polymorphism and Overall Survival in Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy

Integrated Chemoradiotherapy for Recurrent Epithelial Ovarian Cancer

What Influences the Long-Term Survival of Advanced High-Grade Serous Ovarian Cancer?

The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients

The efficacy analysis of topotecan plus platinum in patients with advanced ovarian epithelial carcinoma.

Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases

Factors Affecting Disease Recurrence and the Role of Secondary Therapies in the Management for Patients with Recurrent Ovarian Carcinoma

Survival Impact of Secondary Cytoreductive Surgery for Platinum-Sensitive Relapsed Serous Ovarian Cancer.

Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data